{"id":67080,"date":"2026-06-02T13:55:11","date_gmt":"2026-06-02T05:55:11","guid":{"rendered":"https:\/\/flcube.com\/?p=67080"},"modified":"2026-06-02T13:55:12","modified_gmt":"2026-06-02T05:55:12","slug":"shionogis-xocova-becomes-first-oral-covid-19-post-exposure-prophylaxis-approved-by-fda","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67080","title":{"rendered":"Shionogi&#8217;s XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shionogi &amp; Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4507:TYO\">TYO: 4507<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved <strong>XOCOVA (ensitrelvir)<\/strong>, an <strong>oral antiviral<\/strong>, for <strong>post-exposure prophylaxis (PEP)<\/strong> of <strong>COVID-19<\/strong> in adults and adolescents aged <strong>12 years and older<\/strong> following contact with an infected individual.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-market-distinction\" class=\"wp-block-heading\">Regulatory Milestone &amp; Market Distinction<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shionogi &amp; Co., Ltd. (TYO: 4507)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>XOCOVA (ensitrelvir) \u2013 oral antiviral<\/td><\/tr><tr><td><strong>FDA Approval<\/strong><\/td><td>Post-exposure prophylaxis (PEP) for COVID-19<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adults and adolescents \u226512 years<\/td><\/tr><tr><td><strong>Market Position<\/strong><\/td><td><strong>First and only oral option<\/strong> for COVID-19 PEP<\/td><\/tr><tr><td><strong>Approval Basis<\/strong><\/td><td>Phase 3 SCORPIO-PEP study results<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>June 1, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-3-scorpio-pep-trial\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase 3 SCORPIO-PEP Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Ensitrelvir (n=1,030)<\/th><th>Placebo (n=1,111)<\/th><th>Relative Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Symptomatic COVID-19 Prevention<\/strong><\/td><td>Significantly reduced risk<\/td><td>Reference<\/td><td><strong>67% risk reduction<\/strong><\/td><\/tr><tr><td><strong>Assessment Period<\/strong><\/td><td>Through Day 10 post-exposure<\/td><td>Through Day 10 post-exposure<\/td><td>Statistically significant<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Generally well tolerated<\/td><td>Similar tolerability<\/td><td>Comparable adverse event rates<\/td><\/tr><tr><td><strong>Study Population<\/strong><\/td><td>Uninfected individuals exposed to COVID-19 cases<\/td><td>Same criteria<\/td><td>Robust real-world relevance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The SCORPIO-PEP trial demonstrated that ensitrelvir provides substantial protection against developing symptomatic COVID-19 when administered shortly after exposure to an infected individual.<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Ensitrelvir \u2013 oral antiviral with novel mechanism<\/li>\n\n\n\n<li><strong>Target:<\/strong> SARS-CoV-2 main protease (3CLpro) inhibition<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral tablet for convenient outpatient use<\/li>\n\n\n\n<li><strong>Therapeutic Window:<\/strong> Effective when initiated post-exposure but pre-symptom onset<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First oral agent specifically approved for COVID-19 post-exposure prophylaxis<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-public-health-impact\" class=\"wp-block-heading\">Market Context &amp; Public Health Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Current PEP Landscape<\/strong><\/td><td>No approved oral options; limited alternatives for post-exposure prevention<\/td><\/tr><tr><td><strong>Public Health Need<\/strong><\/td><td>Critical tool for outbreak control in high-risk settings (households, healthcare, congregate living)<\/td><\/tr><tr><td><strong>Competitive Differentiation<\/strong><\/td><td>Unlike vaccines (pre-exposure) or therapeutics (post-infection), fills unique PEP gap<\/td><\/tr><tr><td><strong>Global Pandemic Preparedness<\/strong><\/td><td>Adds important layer to comprehensive COVID-19 prevention strategy<\/td><\/tr><tr><td><strong>Commercial Opportunity<\/strong><\/td><td>Addresses recurring need during seasonal surges and variant waves<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-amp-commercial-outlook\" class=\"wp-block-heading\">Strategic Implications &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Creation:<\/strong> Establishes entirely new treatment category for oral COVID-19 PEP<\/li>\n\n\n\n<li><strong>Healthcare System Integration:<\/strong> Potential for rapid deployment in public health emergency response protocols<\/li>\n\n\n\n<li><strong>Pricing Premium:<\/strong> First-mover advantage supports premium pricing in absence of competition<\/li>\n\n\n\n<li><strong>Global Regulatory Pathway:<\/strong> FDA approval likely to facilitate approvals in other major markets<\/li>\n\n\n\n<li><strong>Stockpiling Potential:<\/strong> Government and institutional procurement opportunities for pandemic preparedness<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The approval positions XOCOVA as a critical addition to the COVID-19 prevention arsenal, offering a convenient oral option to protect individuals immediately following known exposure\u2014potentially reducing transmission chains and preventing severe outcomes in vulnerable populations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial expectations for XOCOVA. Actual results may differ due to risks including market adoption, competitive dynamics, and evolving pandemic conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shionogi &amp; Co., Ltd. (TYO: 4507) announced that the U.S. Food and Drug Administration (FDA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":67082,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[15,423,2673],"class_list":["post-67080","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-product-approvals","tag-shionogi","tag-tyo-4507"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shionogi&#039;s XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shionogi &amp; Co., Ltd. (TYO: 4507) announced that the U.S. Food and Drug Administration (FDA) has approved XOCOVA (ensitrelvir), an oral antiviral, for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older following contact with an infected individual.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67080\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shionogi&#039;s XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA\" \/>\n<meta property=\"og:description\" content=\"Shionogi &amp; Co., Ltd. (TYO: 4507) announced that the U.S. Food and Drug Administration (FDA) has approved XOCOVA (ensitrelvir), an oral antiviral, for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older following contact with an infected individual.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67080\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T05:55:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-02T05:55:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0204.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67080#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67080\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shionogi&#8217;s XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA\",\"datePublished\":\"2026-06-02T05:55:11+00:00\",\"dateModified\":\"2026-06-02T05:55:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67080\"},\"wordCount\":432,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67080#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0204.webp\",\"keywords\":[\"Product approvals\",\"Shionogi\",\"TYO: 4507\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67080#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67080\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67080\",\"name\":\"Shionogi's XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67080#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67080#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0204.webp\",\"datePublished\":\"2026-06-02T05:55:11+00:00\",\"dateModified\":\"2026-06-02T05:55:12+00:00\",\"description\":\"Shionogi & Co., Ltd. (TYO: 4507) announced that the U.S. Food and Drug Administration (FDA) has approved XOCOVA (ensitrelvir), an oral antiviral, for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older following contact with an infected individual.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67080#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67080\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67080#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0204.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0204.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shionogi's XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67080#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shionogi&#8217;s XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shionogi's XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA - Insight, China&#039;s Pharmaceutical Industry","description":"Shionogi & Co., Ltd. (TYO: 4507) announced that the U.S. Food and Drug Administration (FDA) has approved XOCOVA (ensitrelvir), an oral antiviral, for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older following contact with an infected individual.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67080","og_locale":"en_US","og_type":"article","og_title":"Shionogi's XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA","og_description":"Shionogi & Co., Ltd. (TYO: 4507) announced that the U.S. Food and Drug Administration (FDA) has approved XOCOVA (ensitrelvir), an oral antiviral, for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older following contact with an infected individual.","og_url":"https:\/\/flcube.com\/?p=67080","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-02T05:55:11+00:00","article_modified_time":"2026-06-02T05:55:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0204.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67080#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67080"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shionogi&#8217;s XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA","datePublished":"2026-06-02T05:55:11+00:00","dateModified":"2026-06-02T05:55:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67080"},"wordCount":432,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=67080#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0204.webp","keywords":["Product approvals","Shionogi","TYO: 4507"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67080#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67080","url":"https:\/\/flcube.com\/?p=67080","name":"Shionogi's XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=67080#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=67080#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0204.webp","datePublished":"2026-06-02T05:55:11+00:00","dateModified":"2026-06-02T05:55:12+00:00","description":"Shionogi & Co., Ltd. (TYO: 4507) announced that the U.S. Food and Drug Administration (FDA) has approved XOCOVA (ensitrelvir), an oral antiviral, for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older following contact with an infected individual.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67080#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67080"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=67080#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0204.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0204.webp","width":1080,"height":608,"caption":"Shionogi's XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67080#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shionogi&#8217;s XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0204.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67080"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67080\/revisions"}],"predecessor-version":[{"id":67083,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67080\/revisions\/67083"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/67082"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}